The 9MMSpinal Muscular Atrophy Drug Treatment Market is expected to offer an $ opportunity of USD 24,855.2 Million over the analysis period. Market was estimated USD 3,876.2 Million during 2023 and expected to grow at a significant CAGR 19.2% over the projected period. And by the end of 2033, the market is expected to touch USD 28,731.4 Million.
Pipeline drugs expected to provide an opportunity of more than USD 2,341.6 Million during the forecast year.
Disease Overview:A hereditary condition known as spinal muscular atrophy (SMA) impact the central and peripheral neurological systems as well as the voluntary movement of skeletal muscle. The term "spinal" in the disease's name refers to the fact that the majority of the nerve cells that regulate muscles are found in the spinal cord. Since muscles don't get impulses from these nerve cells, SMA is mostly muscular. Read more….
Report has deeply investigated patient’s presentation and tailored treatment
Report has Covered Granular-level Analysis in Each Mapped Market
Spinal Muscular Atrophy, Disease Burden Analysis: (Result shown here is reflecting from meta-analysis, and CSP Analytics Solutions Analysis)
This section explored the epidemiology associated with Spinal Muscular Atrophy across regions
Experts indicated prevalence increased significantly across regions, but gaps in estimates still persist.
Our research report has provided crystal clear view of prevalent pool across regions. Since epidemiology estimation accompanied with lot of complexity, our report has streamlined the estimation process for enhancing market understanding.
Report has also highlighted, impact of improvements in diagnosis, on diagnosis rate (%).
Spinal Muscular Atrophy Cases: 9MM
Spinal Muscular Atrophy accountsfor XX million cases in 9MM
Spinal Muscular Atrophy accountsfor XX million cases in United States
Spinal Muscular Atrophy accountsfor XX million cases in China
Spinal Muscular Atrophy accountsfor XX million cases in India
Spinal Muscular Atrophy accountsfor XX million cases in Japan
Spinal Muscular Atrophy accountsfor XX million cases in Rest of World
Spinal Muscular Atrophy - Treatment Landscape:
However there’re a number of therapies for SMA that prolong life, maintain motor neurones, and increase muscular function, they are not cures. Older individuals with SMA have suffered more motor neurone loss, therapy early in life typically yields higher benefits than treatment later in life. FDA-approved therapies available for the treatment are Nusinersen (Spinraza), Onasemnogene abeparovec-xioi (Zolgensma), and Risdiplam (Evrysdi).
This report section deals with the treatment strategies adopted by healthcare professional while dealing across patients’ segments. Also provided gaps in current treatment and upcoming treatment options.
The treatment of Spinal Muscular Atrophy typically involves the use of Gene Therapy, SMN2 Splicing Modifiers, and Combination Therapies.
Treatment of Spinal Muscular Atrophy’s requires holistic framework to address diverse set of patients. Collaboration among various specialties is imperative to devise tailoring treatment plan. Efforts to encourage diagnosis rate and advocacy at patient and physician level is crucial to provide better therapeutic options.
Report section covers detailed around various types of available treatments
Gene Therapy
SMN2 Splicing Modifiers
Combination Therapies
Also covers patient segment targeted by each therapy type: This section address concerns regarding unaddressed patient pool
Several companies and institutions collaborating to bring out the appropriate treatment solutions
Our report analysis revealed that, there are tremendous opportunities exits in the market in order to close the current market gaps
Recent clinical guidelines enable the streamlining the treatment approaches
Report has examined the how many and what type of cases refer to which type of therapy based on experts’ opinion analysis.
Untreated Prevalent Pool of Spinal Muscular Atrophy
Huge medical unmet need
Advancements in diagnosis tools
Advancements in Treatment Options
Proliferation of novel treatment options
Advent of emerging therapy for developing tailoring treatment
Emergence of Targeted Therapies
Market Challenges: Explored in the report
Limited Treatment Options
High Treatment Costs
Clinical Trial Enrollments
Access to Care and Treatment
Research and development gaps
Misdiagnosis and Underdiagnosis
Lack of adequate treatment compliance and adherence
Spinal Muscular AtrophyMapped Geography: Nine Major Markets (9MM)
Report has fragmented the total market into five regions such as:
United States
5-Europe
Germany
France
Italy
Spain
United Kingdom
Rest of Europe
China
Japan
India
RoW (Rest of World)
Each mapped region has been examined at granular level based on below parameters:
United States Spinal Muscular Atrophy Drug Treatment Market: The Spinal Muscular Atrophy market in the United States is experiencing significant growth, accompanied by rising disease prevalence, advancements in diagnostics, and the development of novel therapies. United States captured around 58.3% of market share in Nine Major Markets. Market is expected to witness the significant upcoming growth, accompanied with rising disease prevalence, advancements in diagnostics, and a robust pipeline of emerging upcoming therapies.
Market Size and Forecast Model 2023-2033
Disease Overview
Current Treatment Approaches
Key Opinion Leader (KOL) Views
Disease Burden Analysis (Prevalence, Diagnosed, Treatable Prevalent Pool Analysis)
Diagnosis and Treatment Guidelines
Drug Share Analysis (%)
Drug Treatment Adherence and Compliance Rate (%)
Annual Cost of Therapy
Market Unmet Need Analysis
5-Europe Spinal Muscular Atrophy Drug Treatment Market
Market Size and Forecast Model 2023-2033
Disease Overview
Current Treatment Approaches
Key Opinion Leader (KOL) Views
Disease Burden Analysis (Prevalence, Diagnosed, Treatable Prevalent Pool Analysis)
Diagnosis and Treatment Guidelines
Drug Share Analysis (%)
Drug Treatment Adherence and Compliance Rate (%)
Annual Cost of Therapy
Current Treatment Landscape and Upcoming therapy Assessment
Market Unmet Need Analysis
Key Players in the Market and their Market share (%)
By Country
United Kingdom
Germany
France
Italy
Spain
Rest of Europe
China Spinal Muscular Atrophy Drug Treatment Market
Market Size and Forecast Model 2023-2033
Disease Overview
Current Treatment Approaches
Key Opinion Leader (KOL) Views
Disease Burden Analysis (Prevalence, Diagnosed, Treatable Prevalent Pool Analysis)
Diagnosis and Treatment Guidelines
Drug Share Analysis (%)
Drug Treatment Adherence and Compliance Rate (%)
Annual Cost of Therapy
Current Treatment Landscape and Upcoming therapy Assessment
Market Unmet Need Analysis
Key Players in the Market and their Market share (%)
India Spinal Muscular Atrophy Drug Treatment Market
Market Size and Forecast Model 2023-2033
Disease Overview
Current Treatment Approaches
Key Opinion Leader (KOL) Views
Disease Burden Analysis (Prevalence, Diagnosed, Treatable Prevalent Pool Analysis)
Diagnosis and Treatment Guidelines
Drug Share Analysis (%)
Drug Treatment Adherence and Compliance Rate (%)
Annual Cost of Therapy
Current Treatment Landscape and Upcoming therapy Assessment
Market Unmet Need Analysis
Key Players in the Market and their Market share (%)
Japan Spinal Muscular Atrophy Drug Treatment Market
Market Size and Forecast Model 2023-2033
Disease Overview
Current Treatment Approaches
Key Opinion Leader (KOL) Views
Disease Burden Analysis (Prevalence, Diagnosed, Treatable Prevalent Pool Analysis)
Diagnosis and Treatment Guidelines
Drug Share Analysis (%)
Drug Treatment Adherence and Compliance Rate (%)
Annual Cost of Therapy
Current Treatment Landscape and Upcoming therapy Assessment
Market Unmet Need Analysis
Key Players in the Market and their Market share (%)
Rest of the World Spinal Muscular Atrophy Drug Treatment Market
Market Size and Forecast Model 2023-2033
Disease Overview
Current Treatment Approaches
Key Opinion Leader (KOL) Views
Disease Burden Analysis (Prevalence, Diagnosed, Treatable Prevalent Pool Analysis)
Diagnosis and Treatment Guidelines
Drug Share Analysis (%)
Drug Treatment Adherence and Compliance Rate (%)
Annual Cost of Therapy
Current Treatment Landscape and Upcoming therapy Assessment
Market Unmet Need Analysis
Key Players in the Market and their Market share (%)
Spinal Muscular Atrophy Competitive Landscape (Existing and Pipeline Players):
Players in Market Space - Players explored in the report has been analyzed at various parameters. Analysis done around, product offerings, pipeline assets, In-licensing and out-licensing opportunities, financial health, market share, collaboration and partnership, patents, funding secures, technology outlook, future strategic move and investment.
Company Profiles:
Biogen
Novartis Pharmaceuticals
Hoffmann-La Roche
Catalyst Pharmaceuticals, Inc.
Lantu Biopharma
NMD Pharma A/S
GeneCradle Inc
Cytokinetics
United BioSource, LLC
Scholar Rock, Inc.
Biocad
MarsiBionics
Genecombio Ltd.
Takeda
Alcyone Therapeutics, Inc
Biohaven Pharmaceuticals, Inc.
Nido Biosciences, Inc.
AnnJi Pharmaceutical Co., Ltd.
Natera, Inc.
Genentech, Inc.
Others
Reason to buy this report:
Fostering Understanding on Spinal Muscular Atrophy Treatment Market
In Order to Understand the Market Potential
Opportunity Analysis (exist in the market for players)
